View Future GrowthRevium Rx 과거 순이익 실적과거 기준 점검 0/6Revium Rx의 수입은 연평균 -69.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 9.7% 증가했습니다.핵심 정보-69.23%순이익 성장률-39.01%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률-219.95%순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.공시 • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0공시 • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.공시 • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.매출 및 비용 세부 내역Revium Rx가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:RVRC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-142231 Dec 250-132230 Sep 250-22230 Jun 250-22231 Mar 250-22231 Dec 240-41231 Dec 230001양질의 수익: RVRC 은(는) 현재 수익성이 없습니다.이익 마진 증가: RVRC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RVRC은 수익성이 없으며 지난 5년 동안 손실이 연평균 69.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RVRC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RVRC은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RVRC는 현재 수익성이 없으므로 자본 수익률이 음수(-219.95%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 11:33종가2026/03/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Revium Rx.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.
공시 • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0
공시 • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.
공시 • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.